Prophetic Woman

Lang, Amy Schrager

doi:10.1525/9780520335370

Cited by 108 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[58][59][60][61][62][63][64] One interesting candidate -VPM1002 -is a recombinant vaccine that was engineered to increase the capacity of the conventional BCG vaccine to promote CD8+ T-cell responses. 57,65,66 VPM1002 expresses an enzyme that acts within infected macrophages to allow translocation of antigens into the cytoplasm, thus increase antigen presentation to CD8+ T-cells. Three doses of the vaccine demonstrated increased safety, immunogenicity, and efficacy in early phase clinical studies when compared to one dose of conventional BCG, and recently entered Phase II/III trials.…”

Section: Bacteriamentioning

confidence: 99%

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti

Jewell

2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Despite the success of vaccines in preventing many infectious diseases, effective vaccines against pathogens with ongoing challenges -such as HIV, malaria, and tuberculosis -remain unavailable. The emergence of new pathogen variants, the continued prevalence of existing pathogens, and the resurgence of yet other infectious agents motivate the need for new, interdisciplinary approaches to direct immune responses. Many current and candidate vaccines, for example, are poorly immunogenic, provide only transient protection, or create risks of regaining pathogenicity in certain immune-compromised conditions. Recent advances in biomaterials research are creating new potential to overcome these challenges through improved formulation, delivery, and control of immune signaling. At the same time, many of these materials systems -such as polymers, lipids, and self-assembly technologies -may achieve this goal while maintaining favorable safety profiles. This review highlights ways in which biomaterials can advance existing vaccines to safer, more efficacious technologies, and support new vaccines for pathogens that do not yet have vaccines. Biomaterials that have not yet been applied to vaccines for infectious disease are also discussed, and their potential in this area is highlighted

show abstract